290 related articles for article (PubMed ID: 15922116)
1. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
3. Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Nakamura K; Yamagishi S; Matsui T; Inoue H
Drugs Exp Clin Res; 2005; 31(4):155-9. PubMed ID: 16223205
[TBL] [Abstract][Full Text] [Related]
4. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Yamagishi S; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
[TBL] [Abstract][Full Text] [Related]
7. Diabetes mellitus, obesity, and hepatic steatosis.
Youssef W; McCullough AJ
Semin Gastrointest Dis; 2002 Jan; 13(1):17-30. PubMed ID: 11944630
[TBL] [Abstract][Full Text] [Related]
8. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
9. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease in severely obese subjects.
Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
[TBL] [Abstract][Full Text] [Related]
12. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
13. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.
Willner IR; Waters B; Patil SR; Reuben A; Morelli J; Riely CA
Am J Gastroenterol; 2001 Oct; 96(10):2957-61. PubMed ID: 11693332
[TBL] [Abstract][Full Text] [Related]
14. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
15. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
16. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH
Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
[TBL] [Abstract][Full Text] [Related]
18. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose.
Rösen P; Osmers A
Horm Metab Res; 2006 Sep; 38(9):575-86. PubMed ID: 16981139
[TBL] [Abstract][Full Text] [Related]
20. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH.
Koike K; Moriya K
J Gastroenterol; 2005 Apr; 40(4):329-36. PubMed ID: 15868369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
